Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
C.AtkinS
A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brains reward center thought to be involved in food noise but only temporarily
Sources: FDA Mounjaro USPI (January 2026) and FDA Zepbound USPI (February 2026)
They work by mimicking the actions of the GLP-1 hormone, which regulates appetite and food intake
CareEdge estimates the Indian GLP-1 market at roughly 1,0001,200 crore in 2025 and projects it could rise nearly fivefold to about 4,5005,000 crore by 2030
Tirzepatide is not indicated for type 1 diabetes and should not be used in combination with other GLP-1 receptor agonists or weight management medications
US$ 28.61
US$ 29.87
US$ 21.09
US$ 23.17
US$ 20.25
US$ 26.80
